Related Experiment Video
Updated: Dec 8, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.6K
Second line salvage systemic therapy for advanced penile cancer
Jad Chahoud1, Monica Tamil2, Andrea Necchi3
1Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL.
Urologic Oncology
|September 20, 2020
Summary
Patients with advanced penile cancer often relapse after chemotherapy. This review covers salvage treatments and ongoing clinical trials for penile cancer, focusing on chemotherapy, targeted therapies, and novel immune-based approaches.
Area of Science:
- Oncology
- Medical Urology
Background:
- Advanced penile cancer frequently relapses following initial cisplatin-based chemotherapy.
- Salvage options including chemotherapy, surgery, and radiation offer limited efficacy for recurrent disease.
Purpose of the Study:
- To review current and emerging salvage systemic therapies for advanced penile cancer.
- To summarize ongoing clinical trials investigating novel treatment strategies.
Main Methods:
- Literature review of available chemotherapy and targeted therapies.
- Summary of interventional clinical trials in penile cancer.
Main Results:
- Limited efficacy of traditional salvage chemotherapy, surgery, and radiation.
- Emerging role of targeted therapies and immunotherapies.
Conclusions:
- There is a critical need for effective salvage treatments for advanced penile cancer.
- Ongoing trials exploring immune and human papilloma virus-based therapies offer future hope.
